metricas
covid
Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Non-convulsive status epilepticus as the initial manifestation in a family with ...
Información de la revista
Vol. 38. Núm. 2.
Páginas 82-86 (marzo 2023)
Visitas
863
Vol. 38. Núm. 2.
Páginas 82-86 (marzo 2023)
Original article
Open Access
Non-convulsive status epilepticus as the initial manifestation in a family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Status epilepticus no convulsivo como manifestación inicial en una familia con arteriopatía autosómica dominante cerebral con infartos subcorticales y leucoencefalopatía (CADASIL)
Visitas
863
F. González
Autor para correspondencia
fabiogonzalezclinicas@yahoo.com

Corresponding author.
, M. Bala, M. Saucedo, L. Bandeo, G. Pacio, A. Chertcoff, L. De Francesco, L. León Cejas, M.S. Pacha, C. Uribe Roca, O. Martínez, M. Fernández Pardal, R. Reisin, P. Bonardo
Servicio de Neurología, Hospital Británico de Buenos Aires, Buenos Aires, Argentina
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (3)
Mostrar másMostrar menos
Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominant small-vessel disease caused by mutations of the NOTCH3 gene. It typically presents with migraine, recurrent brain ischaemia, and cognitive disorders. Seizures rarely present as the initial manifestation, with non-convulsive status epilepticus being even less frequent. We present a series of 3 related patients with this arteriopathy, 2 of whom presented status epilepticus as a manifestation of the disease.

Keywords:
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
CADASIL
Epilepsy
NOTCH3
Non-convulsive status epilepticus
Status epilepticus
Resumen

La arteriopatía autosómica dominante cerebral con infartos subcorticales y leucoencefalopatía es una enfermedad autosómica dominante de pequeños vasos causada por mutaciones del gen NOTCH3. Típicamente se presenta con migraña, eventos isquémicos cerebrales recurrentes y trastornos cognitivos. Las crisis epilépticas son inusuales como manifestación inicial, pero aún más infrecuente es su presentación como status epilepticus no convulsivo. Se presenta una serie familiar de 3 casos con esta arteriopatía, entre los cuales 2 de ellos tuvieron status epilepticus como manifestación de la enfermedad.

Palabras clave:
Arteriopatía cerebral con infartos subcorticales y leucoencefalopatía
CADASIL
Epilepsia
NOTCH3
Status epilepticus no convulsivo
Status epilepticus
Texto completo
Introduction

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominant small-vessel disease caused by mutations of the NOTCH3 gene. It typically presents with migraine, recurrent brain ischaemia, and cognitive disorders. Seizures rarely present as the initial manifestation, with non-convulsive status epilepticus (NCSE) being even less frequent.1 We present a series of 3 related patients with CADASIL, 2 of whom presented status epilepticus as a manifestation of the disease.

Case descriptionPatient 1

The index patient was a 67-year-old woman with a 5-year history of migraine and cognitive disorders (Fig. 1). She consulted due to sudden onset of expressive aphasia and altered awareness. Brain MRI revealed spontaneous T2/FLAIR hyperintensity in the supratentorial region, thalamus, midbrain, and pons, with normal findings on diffusion-weighted sequences (Fig. 2). EEG initially showed epileptiform activity in the left hemisphere, and subsequently detected activity compatible with status epilepticus (Fig. 3). Symptoms improved with levetiracetam and the patient was discharged. However, she presented several recurrences, and was therefore readmitted. A genetic study detected the R1006C NOTCH3 mutation.

Figure 1.

Pedigree chart.

(0.15MB).
Figure 2.

Brain MRI, T2/FLAIR sequence.

(0.18MB).
Figure 3.

Electroencephalography study.

(0.66MB).
Patient 2

Patient 2 was a 65-year-old woman, the sister of patient 1, who consulted due to confusional syndrome and expressive aphasia, before diagnosis of CADASIL was confirmed in patient 1. Brain MRI detected multiple T2-/FLAIR-hyperintense subcortical lesions, with normal results on diffusion-weighted sequences. EEG findings were compatible with status epilepticus. The patient was treated with levetiracetam, which improved symptoms. In the light of the patient’s family history, we suspected CADASIL.

Patient 3

Patient 3 was a 72-year-old man, the brother of patient 1, with history of headache and a stroke 10 years prior to consultation. He reported that his mother had presented similar symptoms to his own. He consulted due to 7 years’ progression of cognitive impairment. Physical examination revealed disorientation in time, with impaired memory and attention, bradykinesia, and retropulsion. Brain MRI detected multiple T2-/FLAIR-hyperintense subcortical lesions in the frontal, parietal, and temporal regions, with normal results on diffusion-weighted sequences. In the light of the patient’s family history, we suspected CADASIL.

Discussion

We describe the cases of at least 2 patients with confirmed NCSE as the initial manifestation of CADASIL, a very unusual form of presentation at the time of diagnosis. To our knowledge, only one case has previously been described of NCSE at onset; that patient presented a different genetic mutation than the one detected in our series. The patient was a 65-year-old woman with a 40-year history of migraine and depression; the initial manifestation of CADASIL was migraine, and the patient presented 3 episodes of sudden onset of language, gait, and sensory alterations, which led to diagnosis of NCSE. That patient presented the C583T NOTCH3 mutation (Table 1).1

Table 1.

Summary of patients with epilepsy as the initial symptom of CADASIL.

Reference  Age of onset (years)/sex  Type of seizures  Treatment  Mutation 
Haan et al.10  42/F  Generalised tonic-clonic  Carbamazepine  ARG182CYS 
Velizarova et al.  30/F  –  Levetiracetam  – 
Haddad et al.11  80/F  Focal/status epilepticus  Levetiracetam/valproate  – 
Oh et al.9  43/M  Generalised tonic-clonic  Oxcarbazepine/topiramate  R544C 
Chen et al.12  12/F  Generalised tonic-clonic  Valproate/lamotrigine  CYS446TYR 
De Freitas et al.  69/F  Focal/generalised tonic-clonic  –  – 
Malandrini et al.  47/F  Generalised tonic-clonic  Phenytoin/phenobarbital  – 
Valko et al.1  61/F  NCSE  Phenytoin  C583T 
Chen et al.12  61/F  Focal/generalised tonic-clonic  Midazolam/phenytoin  CYS446TYR 
Chen et al.12  25/M  Focal/generalised tonic-clonic  Lamotrigine/levetiracetam  CYS446TYR 
Sacco et al.  34/F  Generalised tonic-clonic  BZD  R141C 
Gonzalez et al.  67/F  NCSE  Levetiracetam  R1006C 
Gonzalez et al.  65/F  NCSE  Levetiracetam  R1006C 

BZD: benzodiazepines; NCSE: non-convulsive status epilepticus.

CADASIL is a genetic disease caused by mutations to the NOTCH3 gene, located on chromosome 19p13, which encodes a membrane protein containing epidermal growth factor–like repeat domains; the protein is involved in cell signalling and is extremely important in cell migration during embryogenesis, in arteriovenous differentiation, and in controlling muscle tone in small arteries.2,3 Several mutations have been described in the different exons encoding these domains, some of which appear as clusters associated with ethnicity or geographic origin.4–6 The R1006C mutation was observed in families from a small area of central Italy, extending from the city of Ascoli Piceno to the Adriatic coast, along the river Tronto.7 According to the description of these families, nearly all patients presented the typical initial manifestations of CADASIL, with the exception of one patient who presented psychotic symptoms at onset.8 The main clinical manifestations are recurrent ischaemia, migraine, and progressive cognitive impairment. Seizures are infrequent. They are usually secondary to previous ischaemic lesions, and rarely appear as the initial manifestation of the disease.9–11 They have also been reported in patients with history of migraine or in the context of encephalopathy or coma.12,13

In an extensive series of 102 patients, Dichgans et al.14 report 10 patients with history of seizures, 9 of whom had previously had strokes. Nine of these patients presented generalised tonic-clonic seizures, and one presented focal seizures. Seizures were recurrent in 5 patients, and 3 cases were successfully treated with standard antiepileptic drugs.14 Our series includes 2 related patients who presented NCSE as the initial manifestation of CADASIL.

Conclusion

Seizures are rare in patients with CADASIL, and typically present after stroke. Cases of CADASIL presenting with epilepsy as the initial manifestation are even rarer in the literature. This is the first reported family with CADASIL presenting with NCSE at onset, with a different mutation to that previously described in the only other patient with this clinical picture reported to date.

Conflicts of interest

The authors have no conflicts of interest to declare.

References
[1]
P.O. Valko, M.M. Siccoli, A. Schiller, H.G. Wieser, H.H. Jung.
Non-convulsive status epilepticus causing focal neurological deficits in CADASIL.
BMJ Case Rep, 78 (2009), pp. 1287-1289
[2]
A. Joutel, M. Monet, V. Domenga, F. Riant, E. Tournier-Lasserve.
Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect jagged1 binding and NOTCH3 activity via the RBP/JK signaling pathway.
Am J Hum Genet, 74 (2004), pp. 338-347
[3]
A. Del Río Espínola, E. Solé, J. Montaner.
Fisiopato-logıa del CADASIL.
Med Clin (Barc), 135 (2010), pp. 222-230
[4]
M.T. Dotti, F. Antonio, R. Mazzei, S. Bianchi, O. Scali, F.L. Conforti, et al.
The spectrum of NOTCH3 mutations in 28 Italian CADASIL families.
J Neurol Neurosurg Psychiatry, 76 (2005), pp. 736-738
[5]
R. Grigg, R. Lea, A.A. Sullivan, R. Curtain, J. MacMillian, L. Griffiths.
Identification of a novel mutation C144F in the NOTCH3 gene in an Australian CADASIL pedigree.
[6]
K. Mykkänen, M.L. Savontaus, V. Juvonen, P. Sistonen, S. Tuisku, S. Tuominen, et al.
Detection of the founder effect in Finnish CADASIL families.
Eur J Hum Genet, 12 (2004), pp. 813-819
[7]
A. Cappelli, M. Ragno, G. Cacchiò, M. Scarcella, P. Staffolani, L. Pianese.
High recurrence of the R1006C NOTCH3 mutation in central Italian patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Neurosci Lett, 462 (2009), pp. 176-178
[8]
M. Ragno, L. Pianese, G. Cacchiò, A. Manca, M. Scarcella, S. Silvestri, et al.
Multi-organ investigation in 16 CADASIL families from central Italy sharing the same R1006C mutation.
Neurosci Lett, 506 (2012), pp. 116-120
[9]
J.-H. Oh, B.S. Kang, J.C. Choi.
CADASIL initially presented with a seizure.
J Epilepsy Res, 6 (2016), pp. 104-106
[10]
A.C. Joost Haan, A.J. Saskia, B. Lesnik Oberstein.
MDF a epilepsy in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
Cerebrovasc Dis, 24 (2007), pp. 316-317
[11]
N. Haddad, C. Ikard, K. Hiatt, V. Shanmugam, J. Schmidley.
Recurrent status epilepticus as the primary neurological manifestation of CADASIL: a case report.
Epilepsy Behav Case Rep, 3 (2015), pp. 26-29
[12]
B.S. Chen, J.C. Cleland, R.I. King, N.E. Anderson.
062 Cadasil presenting with focal and generalised epilepsy due to a novel NOTCH3 mutation.
J Neurol Neurosurg Psychiatry, 66 (2018), pp. 36-38
[13]
F. Schon, R.J. Martin, M. Prevett, C. Clough, T.P. Enevoldson, H.S. Markus.
“CADASIL coma”: an underdiagnosed acute encephalopathy.
J Neurol Neurosurg Psychiatry, 74 (2003), pp. 249-252
[14]
M. Oichgans, M. Mayer, I. Uttner, R. Briining, J. Müller Höcker, G. Rungger.
The phenotypic spectrum of CADASIL: clinical findings in 102 cases.
Headache Q, 44 (1999), pp. 731-739
Copyright © 2020. Sociedad Española de Neurología
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos